Castle Biosciences CEO Derek Maetzold reports disposal of common shares valued at $791,790.26
CSTL•CEO reports option exercises and share sales
- Castle Biosciences President and CEO Derek J. Maetzold reported option exercises, acquiring 17,144 common shares at USD 2.39 on July 31 and Aug. 3.
- He sold 17,144 shares at weighted-average prices of about USD 30.15 and USD 30.35 on the same dates.
- Maetzold’s direct common-share holdings ended at 21,479 shares following the transactions.
